Reveal HealthTech, a specialised AI partner for healthcare and life sciences, has successfully raised $7.2 million in its Series A round. This significant capital infusion is exactly what they needed to further their mission of establishing AI as a trusted and accountable tool within the industry.
Funding and investors
Leo Capital, a venture capital fund with a focus on early-stage technology companies, took the lead on this round, with Sanos Capital coming on board as a new investor.
The round also featured continued backing from W Health Ventures and 2070 Health—the original incubators of the company. Their ongoing involvement and continued support are a strong vote of confidence in the company’s model and growth path.
How Reveal HealthTech plans to use the fresh funds?
The new capital will be strategically invested to scale the company’s market presence. This includes expanding their customer-facing teams and commercialising their pre-built AI tools into enterprise-ready products.
They also aim to double down on educational initiatives to help the healthcare sector understand and adopt AI.
About Reveal HealthTech
Reveal HealthTech was founded in 2023 by Sanchit Mullick, Andrew Bravo and Dr Salim Afshar, and has quickly made a name for itself as a dedicated healthcare AI specialist.
Operating from hubs in both New York and Bangalore, the company is on a mission to deliver AI-powered breakthroughs for everyone from Fortune 100 pharma giants to innovative digital health startups.
Their key products leading the charge are:
- BioCanvas®: A platform for building multimodal AI applications, such as tools to speed up clinical trial recruitment.
- Prism AI®: A solution designed to create intelligent agents that automate complex workflows in healthcare.
Leadership and team expertise
Reveal HealthTech’s biggest strength is its leadership team, which uniquely blends top-tier medical and engineering talent.
The team includes alumni from world-class institutions like MIT, Harvard Medical, and UC Berkeley, who’ve also held key roles at leading organisations like Mass General, Boston Children’s Hospital, SpaceX, and NASA.
Investors see this rare mix of deep clinical knowledge and elite tech prowess as the company’s true “superpower.” This combination, essential for scalability, allows them to build AI solutions that are both clinically safe and high-calibre.
What brings investor confidence in Reveal HealthTech?
Investors and founders are aligned on Reveal HealthTech’s expert-led strategy.
Rajul Garg of Leo Capital pointed to the team’s standout strength:
“Meeting with Sanchit, Dr Salim, and the AI leadership team at Reveal made it clear their superpower lies in crafting tailored solutions that demonstrate time-bound, business goodness to clients”.
This focus on nuance over generic solutions is key. It is this understanding of healthcare’s complexity that convinced W Health Ventures, and Dr Pankaj Jethwani specifically, to support Reveal from day one.
Echoing this vision, the company’s founder, Sanchit Mullick, succinctly stated its purpose: “Our mission is simple but bold.” They aspire to leverage AI as a catalyst for progress across the entire healthcare ecosystem, serving everyone from global pharmaceutical giants to emerging startups.
Looking forward
Solving healthcare’s complex problems requires an AI built by those who understand both medicine and technology at the highest level.
With this capital and its unique team, with feet in both clinical and engineering worlds, Reveal HealthTech is powered to execute its core purpose.
-By Alkama Sohail and the AHT team
